The Economic Times

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

The Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approval for semaglutide injections. A diabetes patient raised concerns about the drug's delivery system, alleging it deviates from global standards and poses health risks. The court has directed the CDSCO to consider the patient's representation within two months.